BRPI0918906A2 - Method for producing cetirizine tablets - Google Patents

Method for producing cetirizine tablets

Info

Publication number
BRPI0918906A2
BRPI0918906A2 BRPI0918906A BRPI0918906A BRPI0918906A2 BR PI0918906 A2 BRPI0918906 A2 BR PI0918906A2 BR PI0918906 A BRPI0918906 A BR PI0918906A BR PI0918906 A BRPI0918906 A BR PI0918906A BR PI0918906 A2 BRPI0918906 A2 BR PI0918906A2
Authority
BR
Brazil
Prior art keywords
producing
cetirizine
tablets
cetirizine tablets
producing cetirizine
Prior art date
Application number
BRPI0918906A
Other languages
Portuguese (pt)
Inventor
Indu Shah
Kangping Xiao
Kenneth Day
Satish Kamath
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Publication of BRPI0918906A2 publication Critical patent/BRPI0918906A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
BRPI0918906A 2008-09-05 2009-09-03 Method for producing cetirizine tablets BRPI0918906A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9460508P 2008-09-05 2008-09-05
PCT/US2009/055809 WO2010028101A1 (en) 2008-09-05 2009-09-03 Method for making cetirizine tablets

Publications (1)

Publication Number Publication Date
BRPI0918906A2 true BRPI0918906A2 (en) 2015-12-01

Family

ID=41259594

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918906A BRPI0918906A2 (en) 2008-09-05 2009-09-03 Method for producing cetirizine tablets

Country Status (9)

Country Link
US (1) US8383632B2 (en)
EP (1) EP2344137B1 (en)
CN (1) CN102143737A (en)
AU (1) AU2009288006B2 (en)
BR (1) BRPI0918906A2 (en)
CA (1) CA2734691C (en)
ES (1) ES2564056T3 (en)
RU (1) RU2011112926A (en)
WO (1) WO2010028101A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011110939A2 (en) 2010-03-11 2011-09-15 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
EP2571484A2 (en) * 2010-05-18 2013-03-27 Mahmut Bilgic Effervescent formulations
WO2013058721A1 (en) * 2011-10-13 2013-04-25 Mahmut Bilgic Pharmaceutical granules and production method
CN102716099B (en) * 2012-07-05 2013-10-09 湖南千金湘江药业股份有限公司 Levocetirizine hydrochloride chewable tablet and preparation method thereof
CN102860986A (en) * 2012-09-28 2013-01-09 天津市聚星康华医药科技有限公司 Stable taste-masking levocetirizine medicine composition and preparation method thereof
KR102226833B1 (en) * 2013-06-28 2021-03-12 한미약품 주식회사 Complex granule formulation having improved stability comprising levocetirizine and montelukast
CN104546851B (en) * 2013-10-29 2018-01-02 北京韩美药品有限公司 A kind of particulate composition and preparation method thereof, preparation
CN106177973B (en) * 2014-06-11 2019-10-18 广东东阳光药业有限公司 A kind of cetirizine hydrochloride solid preparation and preparation method thereof
JP2016094364A (en) * 2014-11-14 2016-05-26 ニプロ株式会社 Stabilized intraorally disintegrating formulation in which bitter taste is reduced
US20210236430A1 (en) * 2020-02-03 2021-08-05 Johnson & Johnson Consumer Inc. Single layer chewable tablet comprising cetirizine
EP4178549A1 (en) * 2020-07-10 2023-05-17 Adare Pharmaceuticals, Inc. Swellable oral pharmaceutical compositions
ES3058094T3 (en) 2020-11-18 2026-03-06 Biopharma Synergies S L Orodispersible powder composition comprising an antihistamine compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3185626A (en) * 1963-03-06 1965-05-25 Sterling Drug Inc Tablet coating method
US4543370A (en) * 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4683256A (en) * 1980-11-06 1987-07-28 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4643894A (en) * 1984-07-24 1987-02-17 Colorcon, Inc. Maltodextrin coating
US4828841A (en) * 1984-07-24 1989-05-09 Colorcon, Inc. Maltodextrin coating
US4802924A (en) * 1986-06-19 1989-02-07 Colorcon, Inc. Coatings based on polydextrose for aqueous film coating of pharmaceutical food and confectionary products
NZ233403A (en) * 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
FR2647343B1 (en) * 1989-05-24 1994-05-06 Rhone Poulenc Sante NOVEL POROUS PHARMACEUTICAL FORM AND ITS PREPARATION
JP3703481B2 (en) * 1992-01-17 2005-10-05 バーウィンド・ファーマスーティカル・サーヴィスィーズ・インコーポレーテッド Film coatings and coating compositions based on cellulose polymers and lactose
EP0811374A1 (en) 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
BE1011251A3 (en) * 1997-07-03 1999-06-01 Ucb Sa Pharmaceutical administrable oral, including an active substance and cyclodextrin.
DE19814256A1 (en) * 1998-03-31 1999-10-07 Asta Medica Ag Solid, fast-breaking cetirizine formulations
US6274162B1 (en) * 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
US6602518B2 (en) * 2001-06-28 2003-08-05 Wm. Wrigley Jr. Company Chewable product including active ingredient
US6767200B2 (en) * 2001-09-28 2004-07-27 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
ES2354688T3 (en) 2002-01-15 2011-03-17 Ucb Farchim S.A. FORMULATIONS FOR THE ORAL ADMINISTRATION OF ACTIVE COMPOUNDS.
US7807197B2 (en) * 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
US7879354B2 (en) * 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
DE102005041860A1 (en) 2005-09-02 2007-03-08 Schering Ag Nano-particle embedded- and charged-complex, useful for the production of a pharmaceutical composition, comprises two complex partners, where the complex partner is an embedded anionic and a cationic active substance
EP2178521B1 (en) 2007-07-11 2014-01-15 Fertin Pharma A/S Stable medicated chewing gum comprising cyclodextrin inclusion complex

Also Published As

Publication number Publication date
EP2344137B1 (en) 2015-12-02
AU2009288006B2 (en) 2014-07-17
CA2734691A1 (en) 2010-03-11
AU2009288006A1 (en) 2010-03-11
CA2734691C (en) 2017-05-16
RU2011112926A (en) 2012-10-10
US8383632B2 (en) 2013-02-26
WO2010028101A1 (en) 2010-03-11
US20100062061A1 (en) 2010-03-11
EP2344137A1 (en) 2011-07-20
ES2564056T3 (en) 2016-03-17
CN102143737A (en) 2011-08-03

Similar Documents

Publication Publication Date Title
BRPI0817836A2 (en) Method for beer production
IL263849A (en) A method for producing a glycosylated antibody
BRPI0813903A2 (en) PROCESSES FOR PREPARING PIRAZOIS
BRPI0719843A2 (en) METHOD FOR THE PRODUCTION OF BISBENZOXAZOIS
PL2424657T3 (en) A method for producing a catalyst
BRPI0923282A2 (en) method for producing standardized materials
FI20075795L (en) Method for preparing a sugar product
BRPI0922490A2 (en) Method for beta-santalene production
BRPI0923907A2 (en) Method for producing a lubricant base material
BR112012006620A2 (en) method for manufacturing a cylinder hitch cover
BRPI0816333A2 (en) Method for the production of dimethyl ether
BR112012004101A2 (en) press for producing a buffer
BR112012009974A2 (en) method for producing granules comprising a perticide
BRPI1006763A2 (en) printed material, printed material set and method for producing a printed material set
BRPI0818674A2 (en) METHOD FOR ANTIBODY PRODUCTION
BRPI0811510A2 (en) METHOD FOR MOLD PRODUCTION
BRPI0919835A2 (en) method for the production of polymers
BR112012010861A2 (en) freeze-free device and method for producing a freeze-free device
BRPI0923503A2 (en) method for glycerol production.
BRPI0917206A2 (en) Extended Release Tablet and Method for Manufacturing and Using It
FI20075550A0 (en) A method for producing information
FI20105832A0 (en) A method for making shoes
BRPI0813163A2 (en) METHOD FOR THE PRODUCTION OF CYCLIC POLYSILOXANS
BRPI1010841A2 (en) method for the manufacture of fluoroalkylnitriles
FI20080346A0 (en) Process for making a tablet containing additives

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 9/16 (2006.01), A61K 9/20 (2006.01), A61K 31/

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2686 DE 28-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.